Literature DB >> 16972981

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.

Mats Merup1, Vladimir Lazarevic, Hareth Nahi, Björn Andreasson, Claes Malm, Lars Nilsson, Mats Brune, Katarina LeBlanc, Jack Kutti, Gunnar Birgegård.   

Abstract

Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972981     DOI: 10.1111/j.1365-2141.2006.06302.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

1.  Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Authors:  Markus Ditschkowski; Ahmet H Elmaagacli; Rudolf Trenschel; Tanja Gromke; Nina K Steckel; Michael Koldehoff; Dietrich W Beelen
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

Review 2.  Therapy of myelofibrosis (excluding JAK2 inhibitors).

Authors:  Alessandro Rambaldi
Journal:  Int J Hematol       Date:  2010-02-24       Impact factor: 2.490

Review 3.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 4.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

Review 5.  Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Authors:  Aravind Ramakrishnan; Brenda M Sandmaier
Journal:  Expert Rev Hematol       Date:  2010-02-01       Impact factor: 2.929

6.  Survival following allogeneic transplant in patients with myelofibrosis.

Authors:  Krisstina Gowin; Karen Ballen; Kwang Woo Ahn; Zhen-Huan Hu; Haris Ali; Murat O Arcasoy; Rebecca Devlin; Maria Coakley; Aaron T Gerds; Michael Green; Vikas Gupta; Gabriela Hobbs; Tania Jain; Malathi Kandarpa; Rami Komrokji; Andrew T Kuykendall; Kierstin Luber; Lucia Masarova; Laura C Michaelis; Sarah Patches; Ashley C Pariser; Raajit Rampal; Brady Stein; Moshe Talpaz; Srdan Verstovsek; Martha Wadleigh; Vaibhav Agrawal; Mahmoud Aljurf; Miguel Angel Diaz; Belinda R Avalos; Ulrike Bacher; Asad Bashey; Amer M Beitinjaneh; Jan Cerny; Saurabh Chhabra; Edward Copelan; Corey S Cutler; Zachariah DeFilipp; Shahinaz M Gadalla; Siddhartha Ganguly; Michael R Grunwald; Shahrukh K Hashmi; Mohamed A Kharfan-Dabaja; Tamila Kindwall-Keller; Nicolaus Kröger; Hillard M Lazarus; Jane L Liesveld; Mark R Litzow; David I Marks; Sunita Nathan; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Jacob M Rowe; Bipin N Savani; Mary Lynn Savoie; Sachiko Seo; Melhem Solh; Roni Tamari; Leo F Verdonck; Jean A Yared; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L Scott; Ryotaro Nakamura; Ruben Mesa; Wael Saber
Journal:  Blood Adv       Date:  2020-05-12

Review 7.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

8.  Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Authors:  David S Snyder; Joycelynne Palmer; Karl Gaal; Anthony S Stein; Vinod Pullarkat; Firoozeh Sahebi; Nyana Vora; Ryotaro Nakamura; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

9.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

Authors:  Damiano Rondelli; Judith D Goldberg; Luis Isola; Leah S Price; Tsiporah B Shore; Michael Boyer; Andrea Bacigalupo; Alessandro Rambaldi; Marco Scarano; Rebecca B Klisovic; Vikas Gupta; Bjorn Andreasson; John Mascarenhas; Meir Wetzler; Alessandro M Vannucchi; Josef T Prchal; Vesna Najfeld; Attilio Orazi; Rona S Weinberg; Crystal Miller; Giovanni Barosi; Lewis R Silverman; Giuseppe Prosperini; Roberto Marchioli; Ronald Hoffman
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

10.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; B Douglas Smith; Ivana Gojo; Steven D Gore; Mark J Levis; Hetty E Carraway; Jacqueline M Greer; S Percy Ivy; Keith W Pratz; Michael A McDevitt
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.